Kenvue Inc. (NYSE:KVUE) Shares Sold by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 260,205 shares of the company’s stock after selling 1,738 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Kenvue were worth $5,555,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of KVUE. Morningstar Investment Management LLC boosted its stake in shares of Kenvue by 30.8% in the 4th quarter. Morningstar Investment Management LLC now owns 12,392 shares of the company’s stock valued at $265,000 after buying an additional 2,919 shares during the period. First Bank & Trust raised its holdings in Kenvue by 3.4% in the fourth quarter. First Bank & Trust now owns 94,234 shares of the company’s stock valued at $2,012,000 after acquiring an additional 3,127 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Kenvue by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after acquiring an additional 21,222 shares during the last quarter. Sunpointe LLC acquired a new position in Kenvue during the 4th quarter worth approximately $207,000. Finally, Ieq Capital LLC increased its position in shares of Kenvue by 20.0% in the 4th quarter. Ieq Capital LLC now owns 12,853 shares of the company’s stock valued at $274,000 after purchasing an additional 2,146 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the subject of several recent analyst reports. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Barclays dropped their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. UBS Group decreased their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Stock Performance

Shares of KVUE opened at $23.31 on Friday. The company’s 50 day simple moving average is $21.29 and its 200-day simple moving average is $22.14. The firm has a market cap of $44.68 billion, a PE ratio of 43.97, a price-to-earnings-growth ratio of 2.61 and a beta of 1.45. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.